It shows a high affinity to SSTR1, 2, 3, and 5 [14] and has clinical efficacy [15, 16] with acceptable side effects [28, 29].
In CD, recurrent tumors had significantly higher expression rates of SSTR1 and SSTR4 and significantly lower expression of SSTR5.
Recurrent corticotroph pituitary adenomas show a different SSTR expression with lower SSTR5 levels and higher expression of SSTR1 and SSTR4.
Caption: Figure 1: SSTR1, 2A, 3, 4, and 5 in pancreatic tissue show staining of the pancreatic islets which served as positive controls.
The examples show the expression of SSTR1, 2A, 3, 4, and 5 in three cases of corticotroph pituitary adenoma, ranging from 0 to the maximum ID score of 12.
Esteve et al., "Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2," Proceedings of the National Academy of Sciences of the United States of America, vol.
Gatti et al., "Differential efficacy of SSTR1, -2, and -5 agonists in the inhibition of C6 glioma growth in nude mice, " American Journal of Physiology, vol.